scholarly journals Medical Probiotics Contain Enterococcus faecium, not Enterococcus faecalis

2021 ◽  
Vol 47 (1) ◽  
pp. 38-42
Author(s):  
Nobumasa Yoshida ◽  
Natsumi Kawahara ◽  
Kenji Irimura ◽  
Sachi Fukuhara ◽  
Tomoko Hiyama
Keyword(s):  
Enterococcus Faecalis ◽  
Enterococcus Faecium

scholarly journals Molecular characterization of antimicrobial-resistant Enterococcus faecalis and Enterococcus faecium isolated from layer parent stock

2019 ◽  
Vol 98 (11) ◽  
pp. 5892-5899 ◽  
Author(s):  
Yeong Bin Kim ◽  
Kwang Won Seo ◽  
Jong Bo Shim ◽  
Se hyun Son ◽  
Eun Bi Noh ◽  
...  
Keyword(s):  
Molecular Characterization ◽  
Enterococcus Faecalis ◽  
Enterococcus Faecium ◽  
Parent Stock

The occurrence and transferability of the resistance determinants in 50 amikacin-resistant Enterococcus faecalis and Enterococcus faecium

2003 ◽  
Vol 22 (6) ◽  
pp. 632-633 ◽  
Author(s):  
Helena Bujdáková ◽  
Ivana Krupová ◽  
Miriam Filipová ◽  
Sylvia Benczeová ◽  
Milan Kettner ◽  
...  
Keyword(s):  
Enterococcus Faecalis ◽  
Enterococcus Faecium ◽  
Resistance Determinants

scholarly journals Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
James M. Kidd ◽  
Kamilia Abdelraouf ◽  
Tomefa E. Asempa ◽  
Romney M. Humphries ◽  
David P. Nicolau
Keyword(s):  
Enterococcus Faecalis ◽  
Enterococcus Faecium ◽  
Hill Equation ◽  
Infection Model ◽  
Free Drug Concentration ◽  
Time Curve ◽  
Content Type ◽  
Concentration Time ◽  
The Hill ◽  
Susceptibility Breakpoint

ABSTRACT The Clinical and Laboratory Standards Institute (CLSI) daptomycin MIC susceptibility breakpoint for the treatment of enterococcal infections is ≤4 μg/ml. However, patients receiving daptomycin for the treatment of infections caused by enterococci with MICs of ≤4 μg/ml may experience treatment failures. We assessed the pharmacodynamics of daptomycin against enterococci in a neutropenic murine thigh infection model and determined the exposures necessary for bacteriostasis and a 1-log10-CFU reduction of Enterococcus faecalis and Enterococcus faecium. We further characterized daptomycin efficacy at clinically achievable exposures. Six E. faecium and 6 E. faecalis isolates (daptomycin MICs, 0.5 to 32 μg/ml) were studied. Daptomycin was administered at various doses over 24 h to achieve area under the free drug concentration-time curve-to-MIC ratios (fAUC0–24/MIC) ranging from 1 to 148. Daptomycin regimens that simulate mean human exposures following doses of 6, 8, and 10 mg/kg of body weight/day were also studied. Efficacy was assessed by the differences in the number of log10 CFU per thigh at 24 h. The Hill equation was used to estimate the fAUC0–24/MIC required to achieve bacteriostasis and a 1-log10-CFU reduction. For E. faecium, a 1-log10-CFU reduction required an fAUC0–24/MIC of 12.9 (R2 = 0.71). For E. faecalis, a 1-log10-CFU reduction was not achieved, while the fAUC0–24/MIC required for stasis was 7.2 (R2 = 0.8). With a human-simulated regimen of 6 mg/kg/day, a 1-log10-CFU reduction was observed in 3/3 E. faecium isolates with MICs of <4 μg/ml and 0/3 E. faecium isolates with MICs of ≥4 μg/ml; however, a 1-log10-CFU reduction was not achieved for any of the 6 E. faecalis isolates. These results, alongside clinical data, prompt a reevaluation of the current breakpoint.

Sign in / Sign up

Export Citation Format

Share Document